--- title: "Budesonide Enteric Capsules (Part I): Fluid-Bed Drug Layering and Coating Analysis" date: 2025-12-18T06:47:58Z modified: 2025-12-30T02:12:21Z permalink: "https://www.chinacanaan.com/technology/budesonide-enteric-capsules-fluid-bed-drug-layering-and-coating-analysis/" type: post status: publish excerpt: "" wpid: 5108 categories: - Fluid Bed Granulation - News - Technology featured_image: "https://www.chinacanaan.com/wp-content/uploads/2025/12/6506ee7d-0645-4c30-8138-461b42dcf507.jpg" timestamp: 2025-12-30T02:12:21Z tags: - Fluid Bed Granulation - News - Technology --- **A single capsule represents treatment continuity for millions of patients with IgA nephropathy.** When budesonide enteric capsules were included in China’s national reimbursement system yet soon became difficult to supply, the industry was confronted with a recurring reality: _successful drug innovation alone does not guarantee patient access. The ability to manufacture complex formulations at scale remains the decisive factor in sustaining clinical availability._ In the global nephrology landscape, budesonide enteric capsules are recognized as a targeted therapeutic option for primary IgA nephropathy. By enabling site-specific drug release at the terminal ileum, this formulation significantly reduces systemic corticosteroid exposure and associated adverse effects, offering a differentiated safety and efficacy profile compared with conventional oral steroids. However, following its reimbursement inclusion in 2025, rapidly increasing demand **exposed substantial production constraints driven by process complexity and high equipment requirements. ![](https://www.chinacanaan.com/wp-content/uploads/2025/12/6506ee7d-0645-4c30-8138-461b42dcf507-1024x576.jpg) **An Integrated Manufacturing Approach from Pellets to Capsules** Building on its established expertise in solid dosage equipment and long-term project experience, Canaan has developed an end-to-end manufacturing solution for budesonide enteric capsules, covering micro-pellet coating through to capsule filling. In addition to equipment supply, Canaan provides validated process support from laboratory trials to commercial production, enabling pharmaceutical manufacturers to achieve stable scale-up and consistent output. This article focuses specifically on the **Fluid-bed drug layering and enteric coating process**, a critical determinant of product performance. ## **Why Is This Capsule So Difficult to Manufacture?** The production complexity of budesonide enteric capsules originates from their **multi-layer modified-release architecture** and highly precise enteric coating requirements. Based on **TARGIT™ proprietary technology**, the formulation is designed to ensure drug release exclusively in the terminal ileum, the primary pathological site in IgA nephropathy. This targeted delivery limits systemic exposure to less than 1% of that associated with conventional oral corticosteroids, substantially improving the safety profile. Such precision, however, places stringent demands on process control, coating uniformity, and equipment performance throughout manufacturing. ## **Process and Equipment Constraints as the Primary Capacity Bottleneck** Enteric dosage forms require not only advanced formulation design but also highly specialized manufacturing equipment. In particular, the Fluid-bed coating process directly influences pellet coating uniformity, dissolution behavior consistency, and ultimately therapeutic reliability. Conventional Fluid-bed Granulators often encounter limitations including: ✖ Insufficient pellet fluidization, resulting in uneven coating thickness; ✖ Heavy dependence on operator experience, leading to batch-to-batch variability; ✖ Limited precision in temperature and humidity control, reducing process robustness. **Addressing these challenges has been a core focus of Canaan’s process and equipment development.** ## **Fluid-Bed Coating: Four Technical Enhancements Supporting Controlled Drug Release** To overcome the specific manufacturing challenges of budesonide enteric capsules, Canaan has implemented four key technical solutions: ![](https://www.chinacanaan.com/wp-content/uploads/2025/12/ab4f393c-08dd-4095-be42-6b5781541629.jpg) #### **Uniform Air Distribution Design Through digitally controlled, micron-level gap adjustment across multiple airflow channels, pellets achieve stable and homogeneous fluidization. Each pellet follows a consistent motion trajectory, ensuring uniform coating weight gain and reproducible release characteristics. #### Intelligent Process Control System The control system minimizes operator dependency through automated start-up and standardized process execution. Integrated batch management and traceability functions support process reproducibility and regulatory compliance. #### **Customized Atomization Solutions Atomization systems are customized according to coating formulation properties, enabling uniform droplet distribution and reliable performance even for high-complexity coatings. This approach allows process parameters to be aligned closely with formulation requirements. #### **High-Precision Environmental Regulation A multi-sensor configuration enables accurate control of critical parameters, including temperature (±1 °C), airflow (±5%), and humidity (±0.5 g/kg). This stable process environment provides a reliable foundation for consistent enteric coating performance. ![](https://www.chinacanaan.com/wp-content/uploads/2025/12/企业微信截图_17664570313762-1024x515.png) ## **From a Single Capsule to the Advancement of China’s Pharmaceutical Equipment Industry** The supply shortage of budesonide enteric capsules highlights a fundamental challenge for China’s pharmaceutical industry: transitioning from generic-focused production to innovation-driven development, and from theoretical drug availability to reliable patient access. Canaan Technology is committed to delivering **integrated equipment solutions combined with technical service support**, enabling pharmaceutical manufacturers to overcome production bottlenecks and accelerate the commercialization of advanced domestic formulations. With intelligent pharmaceutical manufacturing systems as the foundation, we look forward to enabling stable and efficient production of life-saving medicines such as budesonide—reducing supply uncertainty for patients and contributing to the realization of the _Healthy China 2030_ vision through reliable access to therapy. ## **Beyond Equipment: Validated Process Pathways and Technical Support** Canaan Technology recognizes that successful large-scale manufacturing of advanced dosage forms depends not only on equipment, but equally on process Know-How and project execution experience. Accordingly, we provide: #### √ **Integrated Pilot and Pharmaceutical Research Platforms** At Canaan’s Solid Dosage R&D Center, customers can conduct pharmaceutical research, process development, formulation optimization, technology transfer, process improvement, and full-scale simulation from laboratory trials to commercial production—significantly reducing development timelines and scale-up risk. #### √ **Proven Industrial Case Experience** Canaan has supported multiple pharmaceutical manufacturers in pilot validation and commercial-scale production of advanced dosage forms, ensuring seamless transitions from development to routine manufacturing. #### √ **Flexible and Customized Manufacturing Solutions** Equipment configurations can be tailored to specific capacity requirements and regulatory pathways, supporting both rapid expansion and compliant product registration. ![](https://www.chinacanaan.com/wp-content/uploads/2025/12/蓝色小人-1-1024x481.gif)